Sanjeeb Sahoo

About

Professional Experience:

Jul. 2005- Continuing Scientist, Institute of Life Sciences, Bhubaneswar, India

Jul. 2004 -Jun. 2005 Research Associate, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA

Sep. 2001-Jun. 2004 Postdoctoral Research Associate, Department of Pharmaceutical Sciences, University of Nebraska Medical Center. Omaha, NE, USA.

Aug.1999 - Aug. 2001 Postdoctoral Research Fellow, Japan Society for Promotion of Science (JSPS) Postdoctoral fellow with Prof. Hiroshi Maeda at Department of Microbiology, Kumamoto University School of Medicine, Kumamoto, Japan.

Mar. 1999 – Aug. 1999 Scientist, Dabur Research Foundation. Dabur India Ltd., India.

Jan. 1998 – Mar.1998 Research Fellow, with Prof. S.S. Davis, Department of Pharmaceutical Sciences, University of Nottingham, Nottingham, U. K.

Distinctions/ Fellowships/ Awards and Achievements
• Among Top 2% Scientists in world ranking brought out by Stanford University, 2020

• Dr. Sahoo’s name has figured in the list of influential researchers of the world released by a US-based firm Clarivate Analytics on the basis of Citations in the year 2019. Only 10 scientists, including Dr. Sahoo from India, made it to the list of 4000 researchers of the world.
• Awarded “SAMANTA CHANDRASEKHARA AWARD”, Orissa Bigyan Academy (2000)

• Awarded International Fellowship for Young Biomedical Scientists from ICMR for four
months in 2008 to work at Creighton University, Omaha, Nebraska, USA

• Awarded Postdoctoral fellowship from the American Heart Association (AHA), United States of America (2002-2004).
• Awarded Japanese Society for Promotion of Science (JSPS) postdoctoral fellowship from the Government of Japan (1999-2001).
• U.S. Patent No-5, 874,111 “Process for the preparation of highly monodispersed hydrophilic polymeric nanoparticles”.
• U. S. Patent No-6, 365, 91 “Formulation of Paclitaxel, its derivatives or its analogs entrapped in to nanoparticles of polymeric micelles, process for preparing same and the use there of. The patented formulation is under clinical trial by Dabur India Ltd, New Delhi, India.
• Awarded travel grants from the School of Pharmacy, University of London to attend the 3rd International symposium on Polymer Therapeutics from Laboratory to Clinical Practice, January 7th –9th 1998, School of Pharmacy, University of London, UK.
• Secured (84.07 percentile) All India Graduate Aptitude Test in Engineering (GATE) in 1996
• Awarded Junior Research Fellowship (JRF, 1996-98) University Grant Commission, Government of India.
• Awarded Senior Research Fellowship (SRF, 1998-1999), University Grant Commission, Government of India.
• Funding: Postdoctoral fellowship from American Heart Association (Heartland affiliated) in the project “Micellar nanosystem for localized arterial delivery of rapamycin to inhibit Restenosis” (July 2002-June 2004, $ 86,879).

Areas of research interest:

• Broad area of Nanobiotechnology.
• Formulation design, development and evaluation of biodegradable nanoparticle based drug and gene delivery systems for treatment of cancer.
• Improvement in drug delivery formulations using macromolecular conjugation of anticancer drugs and proteins. Targeting of drug loaded particulate system for enhanced therapeutic action to specific sites.

Employment

• Institute of Life Sciences Scientist
  2005 - Present

Education

• University of Delhi Ph.D
  1995 - 1999
• University of Delhi MS
  1992 - 1994

Projects & Funding

Projects & funding information is unavailable.

Publications (92)

• Flavonoids for the Treatment of Breast Cancer, Present Status and Future Prospective
  Anti-Cancer Agents in Medicinal Chemistry 2023 DOI: 10.2174/1871520623666221024114521
  +Save
• Advancements in clinical translation of flavonoid nanoparticles for cancer treatment
  OpenNano 2022 DOI: 10.1016/j.onano.2022.100074
  +Save
• Phytochemical based nanomedicine: a panacea for cancer treatment, present status and future prospective
  OpenNano 2022 DOI: 10.1016/j.onano.2022.100055
  +Save
• Biosynthesis of Rutin Trihydrate Loaded Silica Nanoparticles and Investigation of Its Antioxidant, Antidiabetic and Cytotoxic Potentials
  Journal of Inorganic and Organometallic Polymers and Materials 2022 DOI: 10.1007/s10904-022-02269-1
  +Save
• Piperlongumine loaded PLGA nanoparticles inhibit cancer stem-like cells through modulation of STAT3 in mammosphere model of triple negative breast cancer.
  International journal of pharmaceutics 2022 DOI: 10.1016/j.ijpharm.2022.121526
  +Save
• Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
  Current pharmaceutical design 2022 DOI: 10.2174/1381612828666220729104433
  +Save
• Curcumin Encapsulated into Biocompatible Co-Polymer PLGA Nanoparticle Enhanced Anti-Gastric Cancer and Anti-Helicobacter Pylori Effect.
  Asian Pacific journal of cancer prevention : APJCP 2022 DOI: 10.31557/apjcp.2022.23.1.61
  +Save
• Nimbolide-encapsulated PLGA nanoparticles induces Mesenchymal-to-Epithelial Transition by dual inhibition of AKT and mTOR in pancreatic cancer stem cells.
  Toxicology in vitro : an international journal published in association with BIBRA 2021 DOI: 10.1016/j.tiv.2021.105293
  +Save
• Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation.
  Nanomedicine (London, England) 2021 DOI: 10.2217/nnm-2021-0004
  +Save
• Reprogramming Cancer Stem-like Cells with Nanoforskolin Enhances the Efficacy of Paclitaxel in Targeting Breast Cancer.
  ACS applied bio materials 2021 DOI: 10.1021/acsabm.1c00141
  +Save